E-drug: FDA Anti-Counterfeit Drug Meeting
-------------------------------------------------------------------------
[This is an important, although USA oriented initiative. Full details
can be found at the url provided. Please 'repair' url. HH]
USA-FDA: Anti-Counterfeit Drug Initiative - Public Meeting
Summary:
The Food and Drug Administration (FDA) is announcing a public
meeting on the agency's effort to combat counterfeit drugs. The
purpose of the meeting is to enable interested individuals,
organizations, and other stakeholders to present information on all
aspects of the agency's initiative against counterfeit drugs. FDA is
particularly interested in hearing about information related to
technology, public education, regulatory and legislative issues, and
industry and health professional issues. The agency is also inviting
vendors of anti-counterfeit technologies relevant to the pharma-
ceutical industry to display their products for the educational benefit
of FDA and attendees. The objective of the meeting is for FDA to
gather information to assist FDA's counterfeit drug task force in
finalizing its report, which will include recommendations on steps
that FDA, other government agencies, and the private sector can
take to minimize the risks to the public from counterfeit drugs
entering the supply chain.
Dates and Time:
The meeting and vendor display will be held on October 15, 2003,
from 9 a.m. to 5 p.m. Attendees should send notice of intent to
attend the meeting by October 9, 2003. Speakers must register
and submit a short summary of the presentation by September 24,
2003. Presenters must send final electronic presentations in
Microsoft PowerPoint, Microsoft Word, or Adobe Portable
Document Format (PDF) to FDA by close of business on October
3, 2003.
Written and electronic comments will be accepted for consideration
until November 3, 2003. Vendors must register and submit a brief
summary of the product(s) they plan to display by close of business
September 24, 2003.
Addresses:
The public meeting and vendor display will be held at the Four
Points Sheraton Bethesda, 8400 Wisconsin Ave., Bethesda, MD
20814, 301-654-1000. Notice of intent to attend the meeting and
requests to present at the meeting should be sent to Elizabeth
French, Office of Policy (HF-11), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD 20857, 301-827-3360, FAX
301-594-6777, e-mail: <efrench@oc.fda.gov> .
Registration and Requests for Presentation:
If you wish to attend the meeting, please notify Elizabeth French. If
you wish to present at the public meeting, please submit your
request and a summary of your presentation to Elizabeth French at
FDA.
Additional information on the meeting may be obtained at:
<http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leaving
FR.html&log=linklog&to=http://www.fda.gov/oc/initiatives/counterfeit
/>http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leaving
FR.html&log=linklog&to=http://www.fda.gov/oc/initiatives/counterfeit
Dated: September 3, 2003.
Jeffrey Shuren,
Assistant Commissioner for Policy.
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug